findmyKOL

Dan Iosifescu, MD

Enriched profile

Deputy Director, Nathan S. Kline Institute for Psychiatric Research (also Professor of Psychiatry, NYU Grossman School of Medicine) · Nathan S. Kline Institute for Psychiatric Research

ORCIDNPI
Region🇺🇸 Boston, MA · Northeast · United StatesSpecialtyPsychiatryFocusDepression (MDD)+1
Active KOLfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publication2026Online presenceverified 2026Payments2021–2025NIH funding2003–2009

Dan Iosifescu is Deputy Director, Nathan S. Kline Institute for Psychiatric Research (also Professor of Psychiatry, NYU Grossman School of Medicine) at Nathan S. Kline Institute for Psychiatric Research. OpenAlex indexes 351 publications with 22,129 citations (h-index 75); ClinicalTrials.gov lists 14 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 5% of Psychiatry profiles in the findmyKOL directory. Clarivate lists Dan Iosifescu as a Highly Cited Researcher (Cross-Field, 2024).

Data verified 14 Aug 2026

Overview

Updated 27 Aug 2026

Dan Iosifescu, MD, is Deputy Director, Nathan S. Kline Institute for Psychiatric Research (also Professor of Psychiatry, NYU Grossman School of Medicine). The public record shows 351 publications with 22,129 citations (h-index 75), centered on Depression (MDD), Bipolar Disorder. It also documents an investigator role on 14 registered clinical trials, industry payments reported by 6 companies, 2 NIH-funded awards (2003–2009).

  • Most recent indexed publication: 2026 · Proceedings of the National Academy of Sciences of the United States of America
  • Top research focus: Depression (MDD)
  • 14 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 6 companies

Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Depression (MDD)11 trialsMajor Depressive Disorder7 trialsBipolar Disorder3 trialsDepressive Disorder, Treatment-Resistant3 trialsAlzheimer's / Dementia1 trialCognitive Dysfunction1 trial

Research focus

OpenAlex concept fingerprint
Depression (MDD)Bipolar Disorder

Drugs & molecules

across trials, industry payments and publications
Vraylargeneric · CariprazineClinical trialsIndustry payments4Publications

Works with

trial sponsors and companies reporting payments
Boehringer Ingelheim International GmbHClinical trialsIndustry payments8Sage Therapeutics, Inc.Clinical trialsIndustry payments8Boehringer Ingelheim Pharmaceuticals, Inc.Clinical trialsIndustry payments7

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
351publications

Distinct works indexed by OpenAlex, matched via ORCID; 16 in PubMed.

22,129citations

Total citations across indexed works.

75h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
14clinical trials

Investigator role on registered studies.

View trials
6companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments
2NIH grants · 2003–2009

Federally funded research awards.

View funding

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 27 Aug 2026

Listed as an investigator on 14 registered studies on ClinicalTrials.gov. The most recent:

Industry payments

Updated 27 Aug 2026

6 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Nervous system

    94%
    Gabapentinoids17.2%
    Pregabalin100%
    Part D<11 patients
    Benzodiazepine11.6%
    Temazepam59%Alprazolam41%
    Part D<11 patients
  • Cardiovascular

    6%
    Statin6%
    Atorvastatin Calcium100%
    Part D<11 patients

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

Updated 27 Aug 2026

2 NIH research awards on record, funded 20032009 per NIH RePORTER. The latest:

Publications

Updated 27 Aug 2026

Their five most recent publications, matched to their ORCID record and linked to PubMed.

Online presence

Updated 27 Aug 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Owned accounts

public accounts run by this person
  • LinkedIn

    linkedin.com/in/daniosifescu

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com
  • ResearchGate

    researchgate.net/scientific-contributions/Dan-V-Iosifescu-38275871

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net
  • Doximity

    doximity.com/pub/dan-iosifescu-md

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doximity.com

Mentions by others

where others cite or feature them
  • Instagram

    instagram.com/reel/DTJK3iNgkT0

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →instagram.com
  • Other

    emedevents.com/speaker-profile/dan-v-iosifescu-2

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →emedevents.com
  • Spotify

    open.spotify.com/episode/1rljE8e1v7hjmDyEq4Oc8M

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →open.spotify.com
3 more mentions behind the reveal.Reveal →

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 27 Aug 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record

Editorial & leadership roles

journal and society appointments
  • Treasurer and Board Member

    American Society of Clinical Psychopharmacology

    2027
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ascpp.org
  • Member

    American College of Neuropsychopharmacology (ACNP)

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →nki.rfmh.org
  • Distinguished Fellow

    American Psychiatric Association

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →nki.rfmh.org

Highly Cited Researcher

Clarivate's annual list, by award category and year
  • verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →clarivate.com

Awards & honors

honors on the public record
4 more awards behind the reveal.Reveal →

Secondary affiliations

appointments beyond the home institution
  • Professor of Psychiatry

    NYU Grossman School of Medicine

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →nki.rfmh.org
  • verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →nki.rfmh.org
  • Formerly Director

    Mood and Anxiety Disorders Program, Icahn School of Medicine at Mount Sinai

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →nki.rfmh.org

Media & interviews

press, podcasts and appearances

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.